APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis

• Published in: Pathology oncology research Vol. 29; p. 1610976
• Main Authors: Cao, Xiying, Wu, Bingqun, Guo, Shaoming, Zhong, Weixiang, Zhu, Shenyu, Zhang, Zuxiong, Gu, Liang, Li, Hui
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 08.03.2023
• Subjects: APOC1; Apolipoprotein C-I - genetics; bioinformatics; Carcinogenesis - genetics; Cell Transformation, Neoplastic; ESCA; Esophageal Neoplasms - pathology; Esophageal Squamous Cell Carcinoma - pathology; expression; Humans; Pathology and Oncology Archive; Prognosis; Serine; expression; ESCA; prognosis; APOC1; bioinformatics
• ISSN: 1532-2807; 1219-4956; 1532-2807
• DOI: 10.3389/pore.2023.1610976

Esophageal carcinoma (ESCA), a common malignant tumor of the digestive tract with insidious onset, is a serious threat to human health. Despite multiple treatment modalities for patients with ESCA, the overall prognosis remains poor. Apolipoprotein C1 (APOC1) is involved in tumorigenesis as an inflammation-related molecule, and its role in esophageal cancer is still unknown. We downloaded documents and clinical data using The Cancer Genome Atlas (TCGA)and Gene Expression Omnibus (GEO) databases. We also conducted bioinformatics studies on the diagnostic value, prognostic value, and correlation between APOC1 and immune infiltrating cells in ESCA through STRING (https://cn.string-db.org/), the TISIDB (http://cis.hku.hk/TISIDB/) website, and various other analysis tools. In patients with ESCA, APOC1 was significantly more highly expressed in tumor tissues than in normal tissues ( < 0.001). APOC1 could diagnose ESCA more accurately and determine the TNM stage and disease classification with high accuracy (area under the curve, AUC≥0.807). The results of the Kaplan-Meier curve analysis showed that APOC1 has prognostic value for esophageal squamous carcinoma (ESCC) ( = 0.043). Univariate analysis showed that high APOC1 expression in ESCC was significantly associated with worse overall survival (OS) ( = 0.043), and multivariate analysis shows that high APOC1 expression was an independent risk factor for the OS of patients with ESCC ( = 0.030). In addition, the GO (gene ontology)/KEGG (Kyoto encyclopedia of genes and genomes) analysis showed a concentration of gene enrichment in the regulation of T-cell activation, cornification, cytolysis, external side of the plasma membrane, MHC protein complex, MHC class II protein complex, serine-type peptidase activity, serine-type endopeptidase activity, infection, antigen processing and presentation, and graft-versus-host disease (all < 0.001). GSEA (gene set enrichment analysis) showed that enrichment pathways such as immunoregulatory-interactions between a lymphoid and non-lymphoid cell (NES = 1.493, p. adj = 0.023, FDR = 0.017) and FCERI-mediated NF-KB activation (NES = 1.437, p. adj = 0.023, FDR = 0.017) were significantly enriched in APOC1-related phenotypes. In addition, APOC1 was significantly associated with tumor immune infiltrating cells and immune chemokines. APOC1 can be used as a prognostic biomarker for esophageal cancer. Furthermore, as a novel prognostic marker for patients with ESCC, it may have potential value for further investigation regarding the diagnosis and treatment of this group of patients.